This central Canada province is focused on fostering growth for high-growth industries. An interview with Ontario Premier ...

Developers celebrate gains for advances with radiopharmaceuticals while regulators and isotope suppliers work to keep up.

A planned investment deal between the British government and AstraZeneca is not going ahead because it did not “add up for ...

AstraZeneca’s investments in Canada since 2023 now exceed $0.9bn, creating a total of 1,200 new high-skilled jobs. In 2024, ...

Imfinzi has been recommended for approval in the European Union, EU, as monotherapy for the treatment of adults with ...

The mega investment is in line with Astrazeneca’s global ambition to achieve 80 billion dollars in Total Revenue and to bring 20 new medicines to patients around the world by 2030.

(RTTNews) - The U.S. Food and Drug Administration has approved AstraZeneca Plc. (AZN.L, AZN) and Daiichi Sankyo's (DSKYF.PK) ENHERTU (fam-trastuzumab deruxtecan-nxki) for the treatment of adult ...

Cambridge headquartered global pharma company AstraZeneca is investing C$820 million (US$570m) in Canada, creating more than 700 high-skilled jobs across all areas of the business. The investment will ...

The investment will support the move to a larger, state-of-the-art office facility in the Greater Toronto Area, Ontario. New investment in Canada will contribute to AstraZeneca’s global ambition to ...

AstraZeneca will expand the its global R&D hub in Mississauga. This $820 million investment underscores Ontario’s growing prominence in the life sciences sector and will create more than 700 ...

Today, a brief rundown of news involving Merck & Co. and AstraZeneca, as well as updates from AbbVie, Stealth BioTherapeutics and Vigil Neuroscience that you may have missed. Expected readouts in ...